What lessons can be learnt from withdrawal of mibefradil from the market?
Po
A L
AL
Centre for Evidence-Based Pharmacotherapy, University of Nottingham, UK.
Zhang
W Y
WY
D000329:Advertising; D001562:Benzimidazoles / Q000009:adverse effects*; D002121:Calcium Channel Blockers / Q000009:adverse effects*; D017277:Drug Approval; D004347:Drug Interactions; D005060:Europe; D006801:Humans; D020748:Mibefradil; D011358:Product Surveillance, Postmarketing; D013764:Tetrahydronaphthalenes / Q000009:adverse effects*; D014481:United States
D001562:Benzimidazoles; D002121:Calcium Channel Blockers; D013764:Tetrahydronaphthalenes; D020748:Mibefradil